Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.45 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.40 |
| ▸ | CDC25B | P30305 | 4/20 | 0.40 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.40 |
| ▸ | CDC25A | P30304 | 2/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19903806 | 0.82 | LMNA (0.59) | KLK7KLK5PPARAPTPN1CDC25B | |
| SCHEMBL16158925 | 0.81 | KLK7 (0.51) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL16158881 | 0.81 | KLK7 (0.51) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL10333714 | 0.74 | TP53 (0.46) | CTSSPTPN1CDC25BPTPN2CDC25A | |
| SCHEMBL16144925 | 0.73 | PTPN1 (0.56) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL16144930 | 0.73 | PTPN1 (0.56) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL15569246 | 0.73 | PPARA (0.60) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL8138595 | 0.73 | PPARA (0.60) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL7518373 | 0.73 | PPARA (0.74) | KLK7KLK5PPARASYKCTSS | |
| SCHEMBL31372427 | 0.73 | PPARA (0.60) | KLK7KLK5PPARASYKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | KLK7 1552/4885KLK5 1459/4885PPARA 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.